CA2383773A1 — Methods and compositions for treating autoimmune disease
Assigned to Boehringer Ingelheim Pharmaceuticals Inc · Expires 2001-03-08 · 25y expired
What this patent protects
The present invention provides methods and compositions for treating auto-immune disease. The methods of the present invention comprise administering to a mammal diagnosed with an auto-immune disease a synergistic ratio of (i) an agent that regulates ICAM-LFA-1 interaction, and (…
USPTO Abstract
The present invention provides methods and compositions for treating auto-immune disease. The methods of the present invention comprise administering to a mammal diagnosed with an auto-immune disease a synergistic ratio of (i) an agent that regulates ICAM-LFA-1 interaction, and (ii) an agent that regulates CD40-CD40 ligand interaction. The compositions of the present invention comprise a synergistic ratio of (i) an agent that regulates ICAM-LFA-1 interaction, and (ii) an agent that regulates CD40-CD40 ligand interaction.
Drugs covered by this patent
- Cytarabine (Cytarabine) · Nippon Shinyaku Co., Ltd.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.